Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKSNASDAQ:BCRXNASDAQ:FOLDNASDAQ:IONS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$28.75-0.9%$30.10$22.90▼$36.45$4.78B0.441.73 million shs1.12 million shsBCRXBioCryst Pharmaceuticals$8.95-0.8%$10.04$6.02▼$11.31$1.89B1.043.03 million shs1.41 million shsFOLDAmicus Therapeutics$6.16+3.4%$6.20$5.51▼$12.65$1.83B0.513.16 million shs3.12 million shsIONSIonis Pharmaceuticals$42.98-1.4%$34.97$23.95▼$52.34$6.94B0.231.60 million shs1.34 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-0.86%-0.28%-8.06%-4.36%+18.65%BCRXBioCryst Pharmaceuticals-0.83%-7.40%-20.06%+30.97%+39.55%FOLDAmicus Therapeutics+3.45%+8.17%-1.68%-17.93%-37.26%IONSIonis Pharmaceuticals-1.40%+8.04%+23.65%+58.66%-5.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKSAlkermes4.913 of 5 stars4.43.00.04.22.82.51.9BCRXBioCryst Pharmaceuticals4.4702 of 5 stars4.52.00.04.21.81.70.6FOLDAmicus Therapeutics3.7078 of 5 stars3.41.00.04.30.60.01.9IONSIonis Pharmaceuticals4.6091 of 5 stars4.42.00.03.02.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.83Moderate Buy$40.0039.13% UpsideBCRXBioCryst Pharmaceuticals 2.90Moderate Buy$16.7086.70% UpsideFOLDAmicus Therapeutics 2.70Moderate Buy$16.22163.56% UpsideIONSIonis Pharmaceuticals 2.78Moderate Buy$58.2535.53% UpsideCurrent Analyst Ratings BreakdownLatest BCRX, ALKS, IONS, and FOLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025BCRXBioCryst PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $15.007/1/2025IONSIonis PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$51.00 ➝ $57.006/30/2025BCRXBioCryst PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$13.006/30/2025BCRXBioCryst PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $18.006/26/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/25/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.006/17/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$33.00 ➝ $42.006/12/2025IONSIonis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$45.00 ➝ $48.005/28/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy$45.005/20/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.005/13/2025ALKSAlkermesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.56B3.04$2.63 per share10.94$9.05 per share3.18BCRXBioCryst Pharmaceuticals$450.71M4.15N/AN/A($2.30) per share-3.89FOLDAmicus Therapeutics$528.29M3.59N/AN/A$0.65 per share9.47IONSIonis Pharmaceuticals$705M9.70N/AN/A$3.73 per share11.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0913.7620.991.8023.30%27.52%17.98%7/23/2025 (Estimated)BCRXBioCryst Pharmaceuticals-$88.88M-$0.26N/AN/A2.58-10.62%N/A-11.06%8/4/2025 (Estimated)FOLDAmicus Therapeutics-$56.11M-$0.09N/A14.31N/A-5.41%4.67%1.05%8/14/2025 (Estimated)IONSIonis Pharmaceuticals-$453.90M-$2.99N/AN/AN/A-63.65%-91.85%-15.77%7/30/2025 (Estimated)Latest BCRX, ALKS, IONS, and FOLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/23/2025Q2 2025ALKSAlkermes$0.42N/AN/AN/A$343.20 millionN/A5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 million4/30/2025Q1 2025IONSIonis Pharmaceuticals-$1.07-$0.93+$0.14-$0.93$144.31 million$132.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ABCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.332.92BCRXBioCryst PharmaceuticalsN/A2.932.88FOLDAmicus Therapeutics2.023.342.47IONSIonis Pharmaceuticals2.639.669.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%BCRXBioCryst Pharmaceuticals85.88%FOLDAmicus TherapeuticsN/AIONSIonis Pharmaceuticals93.86%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%BCRXBioCryst Pharmaceuticals4.80%FOLDAmicus Therapeutics2.20%IONSIonis Pharmaceuticals2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800164.90 million157.65 millionOptionableBCRXBioCryst Pharmaceuticals530209.25 million199.21 millionOptionableFOLDAmicus Therapeutics480307.93 million301.16 millionOptionableIONSIonis Pharmaceuticals1,069159.16 million155.02 millionOptionableBCRX, ALKS, IONS, and FOLD HeadlinesRecent News About These Companies10 Analysts Assess Ionis Pharmaceuticals: What You Need To KnowJuly 3 at 3:14 PM | nasdaq.comShould You Buy Ionis Pharmaceuticals (IONS) After Golden Cross?July 3 at 10:56 AM | zacks.comIonis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?July 3 at 9:21 AM | zacks.comIonis Pharmaceuticals (NASDAQ:IONS) Trading 7.9% Higher - Here's What HappenedJuly 2 at 2:57 PM | marketbeat.comBarclays Upgrades Ionis Pharmaceuticals (IONS)July 2 at 6:15 AM | msn.comIonis Pharmaceuticals (NASDAQ:IONS) Upgraded at BarclaysJuly 2 at 2:37 AM | americanbankingnews.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 2 at 2:42 AM | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Rating Increased to Overweight at BarclaysJuly 1 at 8:25 AM | marketbeat.comIonis: After Years Of Investment, The Wholly-Owned Payoff Is In SightJune 29, 2025 | seekingalpha.comSovran Advisors LLC Purchases 157,092 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)June 29, 2025 | marketbeat.comBiogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 ResultsJune 28, 2025 | msn.comHC Wainwright Reaffirms "Buy" Rating for Ionis Pharmaceuticals (NASDAQ:IONS)June 27, 2025 | americanbankingnews.comIONS - Ionis Pharmaceuticals Inc Sustainability - MorningstarJune 26, 2025 | morningstar.comMSalanersen shines in early spinal muscular atrophy researchJune 26, 2025 | thepharmaletter.comTIonis Pharmaceuticals (NASDAQ:IONS) Given Buy Rating at HC WainwrightJune 26, 2025 | marketbeat.comIonis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 resultsJune 25, 2025 | businesswire.comIONS - Ionis Pharmaceuticals Inc Executives - MorningstarJune 24, 2025 | morningstar.comMIonis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to RetireJune 20, 2025 | msn.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Acquired by GAMMA Investing LLCJune 17, 2025 | marketbeat.comIonis Treats First Patient in Phase III Antisense Oligonucleotide Trial in Angelman SyndromeJune 12, 2025 | precisionmedicineonline.comPIonis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026June 12, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!By Thomas Hughes | June 16, 2025View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!Analysts Supercharge AMD Stock Ahead of Q2 AI CatalystBy Thomas Hughes | June 26, 2025View Analysts Supercharge AMD Stock Ahead of Q2 AI CatalystAs Oil Prices Rebound, These Stocks Could Fuel the Next RallyBy Sarah Horvath | June 9, 2025View As Oil Prices Rebound, These Stocks Could Fuel the Next Rally3 Growth Stocks Too Small for Institutions to BuyBy Gabriel Osorio-Mazilli | June 19, 2025View 3 Growth Stocks Too Small for Institutions to Buy2 Under the Radar Space & Defense Stocks With Huge PotentialBy Leo Miller | July 1, 2025View 2 Under the Radar Space & Defense Stocks With Huge PotentialBCRX, ALKS, IONS, and FOLD Company DescriptionsAlkermes NASDAQ:ALKS$28.75 -0.25 (-0.86%) Closing price 07/3/2025 03:26 PM EasternExtended Trading$28.75 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.BioCryst Pharmaceuticals NASDAQ:BCRX$8.94 -0.08 (-0.83%) Closing price 07/3/2025 03:51 PM EasternExtended Trading$8.94 0.00 (0.00%) As of 07/3/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Amicus Therapeutics NASDAQ:FOLD$6.16 +0.21 (+3.45%) Closing price 07/3/2025 03:39 PM EasternExtended Trading$6.08 -0.08 (-1.22%) As of 07/3/2025 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Ionis Pharmaceuticals NASDAQ:IONS$42.98 -0.61 (-1.40%) Closing price 07/3/2025 02:44 PM EasternExtended Trading$42.64 -0.34 (-0.79%) As of 07/3/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
